| 2024-03-27 |
详情>>
股本变动：
变动后总股本113.54万股
|
| 2024-03-27 |
详情>>
业绩披露：
2023年年报每股收益-10.66美元,归母净利润-863.2万美元,同比去年增长47.16%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-8.18美元,归母净利润-657.8万美元,同比去年增长53.40%
|
| 2023-09-12 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-0.35美元,归母净利润-534.9万美元,同比去年增长30.59%
|
| 2023-06-14 |
股东大会：
将于2023-07-27召开股东大会
会议内容 ▼▲
- 1.To elect four directors to serve until the next annual meeting of stockholders or until their respective successors are duly elected and qualified;
2.To ratify the selection of Moss Adams LLP as the independent registered public accounting firm for Ampio Pharmaceuticals, Inc. for the year ending December 31, 2023;
3.To approve an amendment to the Ampio Pharmaceuticals certificate of incorporation to effect a reverse stock split of the Company’s shares of common stock at a ratio not less than 5-to-1 and not greater than 20-to-1, with the exact ratio to be set within that range at the discretion of our Board of Directors before July 20, 2024 without further approval or authorization of our stockholders;
4.To approve the 2023 Stock and Incentive Plan;
5.To approve an adjournment of the Annual Meeting to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 3.
|
| 2023-05-11 |
详情>>
内部人交易：
Stevens David R共交易3笔
|
| 2023-05-08 |
详情>>
业绩披露：
2023年一季报每股收益-0.26美元,归母净利润-397.8万美元,同比去年增长29.42%
|
| 2023-03-27 |
详情>>
业绩披露：
2022年年报每股收益-1.08美元,归母净利润-1633.7万美元,同比去年增长4.32%
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.94美元,归母净利润-1411.7万美元,同比去年增长-30.1%
|
| 2022-10-04 |
复牌提示：
2022-10-03 13:05:29 停牌，复牌日期 2022-10-04 08:14:00
|
| 2022-09-12 |
股东大会：
将于2022-10-13召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Ampio Pharmaceuticals certificate of incorporation to effect a reverse stock split of the Company’s shares of common stock at a ratio not less than 5-to-1 and not greater than 15-to-1, with the exact ratio to be set within that range at the discretion of our Board of Directors before October 13, 2023 without further approval or authorization of our stockholders.
2.To approve an adjournment of the Special Meeting to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1.
|
| 2022-08-09 |
详情>>
业绩披露：
2022年中报每股收益-0.03美元,归母净利润-770.6万美元,同比去年增长-6.7%
|
| 2022-07-05 |
股东大会：
将于2022-08-10召开股东大会
会议内容 ▼▲
- 1.To elect four directors to serve until the next annual meeting of stockholders or until their respective successors are duly elected and qualified.
2.To ratify the selection of Moss Adams LLP as the independent registered public accounting firm for Ampio Pharmaceuticals, Inc. for the year ending December 31, 2022;
3.To approve an amendment to the Ampio Pharmaceuticals certificate of incorporation to effect a reverse stock split of the Company’s shares of common stock at a ratio not less than 5-to-1 and not greater than 15-to-1, with the exact ratio to be set within that range at the discretion of our Board of Directors before August 10, 2023 without further approval or authorization of our stockholders.
|
| 2022-05-16 |
详情>>
业绩披露：
2022年一季报每股收益-0.02美元,归母净利润-563.6万美元,同比去年增长-53.7%
|
| 2022-03-29 |
详情>>
业绩披露：
2021年年报每股收益-0.09美元,归母净利润-1707.5万美元,同比去年增长-7.43%
|
| 2022-03-29 |
财报披露：
美东时间 2022-03-29 盘后发布财报
|
| 2021-11-10 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.05美元,归母净利润-1085.1万美元,同比去年增长3.78%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-06-30 |
股东大会：
将于2021-08-14召开股东大会
会议内容 ▼▲
- 1.To elect five directors, nominated by our Board of Directors, to serve until our 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”) and until their respective successors are duly elected and qualified or their earlier resignation or removal.
2.To ratify the selection of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To hold an advisory (non-binding) vote to approve the compensation of the Company’s named executive officers, as disclosed in the proxy statement.
4.To consider and vote upon such other business as may properly come before the meeting or any adjournment(s) or postponement(s) thereof.
|
| 2020-10-30 |
股东大会：
将于2020-12-12召开股东大会
会议内容 ▼▲
- 1.To elect five directors, nominated by our Board of Directors, to serve until our 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”) and until their respective successors are duly elected and qualified or their earlier resignation or removal.
2.To ratify the selection of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
|
| 2019-10-31 |
股东大会：
将于2019-12-14召开股东大会
会议内容 ▼▲
- (1)To elect five directors, nominated by our Board of Directors, to serve until our 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) and until their respective successors are duly elected and qualified or their earlier resignation or removal.
(2)To ratify the selection of Moss Adams LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
(3)To consider and vote upon a proposal to approve an amendment to the Certificate of Incorporation to increase the number of shares of authorized Common Stock.
(4)To consider and vote upon a proposal to approve the adoption of our 2019 Stock and Incentive Plan.
(5)To consider and vote upon a proposal to approve an amendment to the Company’s bylaws to adopt majority voting for uncontested elections of directors.
(6)To consider and vote to authorize the Company to adjourn the annual meeting if the meeting is convened and a quorum is present but there are not sufficient votes to approve the foregoing proposals to enable the solicitation of additional proxies.
(7)To transact such other business as may properly come before the meeting or any adjournment(s) thereof.
|
| 2018-10-31 |
股东大会：
将于2018-12-15召开股东大会
会议内容 ▼▲
- 1.To elect five directors, nominated by our Board of Directors, to serve until our 2019 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified or their earlier resignation or removal.
2.To ratify the selection of Plante Moran, PLLC (formerly EKS&H LLLP) as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
3.To hold an advisory (non-binding) vote to approve the Company’s executive compensation.
4.To hold an advisory (non-binding) vote on the frequency of future advisory votes on executive compensation.
5.To transact such other business as may properly come before the meeting or any adjournment(s) thereof.
|
| 2017-08-29 |
股东大会：
将于2017-09-16召开股东大会
会议内容 ▼▲
- (1)To elect five directors, nominated by our Board of Directors, to serve until our 2017 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified or their earlier resignation or removal.
(2)To ratify the selection of EKS&H LLLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
(3)To consider and vote upon a proposal to approve an amendment to the Certificate of Incorporation to increase the number of shares of authorized Common Stock.
(4)To transact such other business as may properly come before the meeting or any adjournment(s) thereof.
|
| 2016-11-22 |
股东大会：
将于2017-01-07召开股东大会
会议内容 ▼▲
- (1)To elect five directors, nominated by our Board of Directors, to serve until our 2017 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified or their earlier resignation or removal.
(2)To ratify the selection of EKS&H LLLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
(3)To transact such other business as may properly come before the meeting or any adjournment(s) thereof.
|
| 2015-11-12 |
股东大会：
将于2015-12-12召开股东大会
会议内容 ▼▲
- 1.To elect five directors, nominated by our Board of Directors, to serve until our 2016 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified or their earlier resignation or removal.
2.To hold an advisory (non-binding) vote to approve the Company’s executive compensation.
3.To ratify the selection of EKS&H LLLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
4.To transact such other business as may properly come before the meeting or any adjournment(s) thereof.
|